Replication and improving the evidence base around HIV prevention and treatment
On 6 November 2017, 3ie’s Washington Office hosted an interactive presentation and to discuss the results of the 3ie-funded replication studies. The panels discussed issues around HIV prevention and treatment, research transparency and replication. Each presentation was followed by a Q&A session.
Three decades of work on HIV prevention has yielded a series of effective biomedical, behavioural and structural interventions. Many impact evaluations have shown the potential for impact of these interventions in reducing the incidence of HIV and the associated human and economic costs. However, scaling up evidence-informed interventions requires study results to be carefully reviewed, understood and confirmed. With this in mind, 3ie, in partnership with the Bill and Melinda Gates Foundation, funded five replication studies of HIV prevention and treatment impact evaluations. The topics covered under this replication window include conditional cash transfers for prevention, antiretroviral treatment, and PEPFAR funding results, among others.
On 6 November 2017, 3ie’s Washington Office hosted an interactive presentation and to discuss the results of the 3ie-funded replication studies. The panels discussed issues around HIV prevention and treatment, research transparency and replication. Each presentation was followed by a Q&A session. If you have any questions about the event or the replication window, please contact Scott Neilitz at sneilitz@3ieimpact.org.